BioNexus Gene Lab Corp. Research and Development Expense
BioNexus Gene Lab Corp. (BGLC) reported Research and Development Expense of $13.67 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- BioNexus Gene Lab Corp. research and development expense for the quarter ending 2026-06-30 was $13.67K, a 8.87% increase year-over-year.
- BioNexus Gene Lab Corp. research and development expense for the quarter ending 2026-03-31 was $14.49K, a 19.34% increase year-over-year.
- BioNexus Gene Lab Corp. research and development expense for the quarter ending 2025-12-31 was $11.10K, a 36.20% decline year-over-year.
- BioNexus Gene Lab Corp. research and development expense for the quarter ending 2025-09-30 was $14.88K, a 42.46% increase year-over-year.
- BioNexus Gene Lab Corp. research and development expense for fiscal 2025 was $50.67K, a 6.65% increase from fiscal 2024.
- BioNexus Gene Lab Corp. research and development expense for fiscal 2024 was $47.51K, a 13.59% decline from fiscal 2023.
- BioNexus Gene Lab Corp. research and development expense for fiscal 2023 was $54.98K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.67K 10-Q · filed 2026-08-14 | $28.16K 10-Q · filed 2026-08-14 | $39.26K derived: sum of 3 quarters · filed 2026-08-14 | $54.13K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $14.49K 10-Q · filed 2026-05-15 | $25.59K derived: sum of 2 quarters · filed 2026-05-15 | $40.46K derived: sum of 3 quarters · filed 2026-05-15 | $53.02K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $11.10K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $25.97K derived: sum of 2 quarters · filed 2026-04-14 | $38.53K derived: sum of 3 quarters · filed 2026-08-14 | $50.67K 10-K · filed 2026-04-14 |
| 2025-09-30 | $14.88K 10-Q · filed 2025-11-14 | $27.43K derived: sum of 2 quarters · filed 2026-08-14 | $39.57K 10-Q · filed 2025-11-14 | $56.97K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $12.56K 10-Q · filed 2026-08-14 | $24.70K 10-Q · filed 2026-08-14 | $42.09K derived: sum of 3 quarters · filed 2026-08-14 | $52.53K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $12.14K 10-Q · filed 2026-05-15 | $29.54K derived: sum of 2 quarters · filed 2026-05-15 | $39.98K derived: sum of 3 quarters · filed 2026-05-15 | $48.17K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $17.40K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $27.84K derived: sum of 2 quarters · filed 2026-04-14 | $36.04K derived: sum of 3 quarters · filed 2026-04-14 | $47.51K 10-K · filed 2026-04-14 |
| 2024-09-30 | $10.44K 10-Q · filed 2025-11-14 | $18.64K derived: sum of 2 quarters · filed 2025-11-14 | $30.11K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $8.20K 10-Q · filed 2025-08-18 | $19.67K 10-Q · filed 2025-08-18 | ||
| 2024-03-31 | $11.47K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $54.98K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |